This article was originally published in The Gray Sheet
Executive SummaryMinneapolis, Minnesota device firm submits 510(k) to FDA for its Perma-Seal dialysis access graft. The company describes the graft as a "synthetic conduit for use as a point of vascular access in kidney dialysis patients"
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.